LABT Lakewood-Amedex Biotherapeutics Inc.
-
Lakewood-Amedex Biotherapeutics Missed Consensus Estimates
Thursday, August 13, 2026 · 12:00 AM ET
Lakewood-Amedex Biotherapeutics (LABT) reported a loss of $2.75 per share on revenue of $0.00 million for the second quarter ended June 2026. The consensus earnings estimate was $0.65 per share. The company missed consensus estimates by 523.08%.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($2.75)
Earnings Whisper®
—
Consensus Estimate
$0.65
Earnings Surprise
Earnings Growth—
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—